NeuroVive" NEWS RELEASE NeuroVive and Sihuan Pharmaceutical to develop and commercialize CicloMulsion® and NeuroSTAT® for cardio- and neuroprotection in China Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. for the development and commercialization in China of NeuroVive's most clinically advanced products CicloMulsion® and NeuroSTAT®. Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China and the market leader in the fast-growing Chinese cardio-cerebral vascular (CCV) drugs market. The agreement was entered into by Sihuan Pharmaceutical through its wholly- owned subsidiary Sun Moral International (HK) Ltd. and by NeuroVive through its subsidiary NeuroVive Pharmaceutical Asia Ltd. CicloMulsion® and NeuroSTAT8 are in clinical development by NeuroVive for the treatment of heart reperfusion injury after stenting and traumatic brain injury respectively. These are indications of huge medical need for which there are currently no approved pharmaceutical treatment options. Both products act to prevent the death of mitochondria in damaged cells and the cascade of intracellular biochemical events that lead to secondary tissue damage following a traumatic injury. By protecting a cell's mitochondria NeuroVive's products ensure that energy production is preserved and a damaged cell's normal regenerative mechanisms can act to repair and maintain the cell. CicloMulsion® and NeuroSTAT® contain cyclosporine which, by inhibiting cyclophilin D, prevents the disruption of the membrane of the mitochondria. Sihuan is a leading Chinese pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China. It has a proven track record in R&D, manufacturing, sales and marketing of cardio-cerebral vascular drugs. Its nationwide distribution network covers over 10,000 h